Ovarian Cancer Population Screening and Mortality After Long-Term Follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A Randomised Controlled Trial
Usha Menon, Aleksandra Gentry‐Maharaj, Matthew Burnell, Naveena Singh, Andy Ryan, Chloe Karpinskyj, Giulia Carlino, Julie Taylor, Susan Massingham, Maria Raikou, Jatinderpal Kalsi, Robert Woolas, Ranjit Manchanda, Rupali Arora, Laura Casey, Anne Dawnay, Stephen Dobbs, Simon Leeson, Tim Mould, Mourad W. Seif, Aarti Sharma, Karin Williamson, Yiling Liu, Lesley Fallowfield, Alistair McGuire, Stuart Campbell, Steven J. Skates, Ian Jacobs, Mahesh Parmar
Abstract
(Abstracted from Lancet 2021;397:2182–2193) Ovarian cancer is most commonly diagnosed at an advanced stage (3 or 4) and remains the deadliest gynecologic malignancy. When diagnosed at stage 1, a survival rate of greater than 90% has been demonstrated, compared with a 5-year survival rate of 27% and 13% for stage 3 and stage 4 disease, respectively.